FDA Classifies Medtronic Harmony Recall as Class I - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Classifies Medtronic Harmony Recall as Class I

Distal tip detachment during implantation may necessitate retrieval of the detached tip through an endovascular or surgical procedure.

  • By

  • Kathryn Wighton

  • July 15, 2026

  • 2 min

Share

Objective:

To inform about the FDA's classification of Medtronic's Harmony Delivery Catheter System recall due to a manufacturing issue.

Approach:
  • Recall Classification: The FDA classified the recall as Class I due to a manufacturing issue affecting specific catheter systems.
  • Affected Devices: The recall affects 1,881 devices distributed in the US and internationally.
  • Device Function: The Harmony Delivery Catheter System is used for placing the Harmony transcatheter pulmonary valve in patients with severe pulmonary regurgitation.
  • Risks Identified: Potential risks include distal tip detachment, prolonged procedure time, tissue damage, and other complications.
  • Patient Guidance: Patients with an implanted Harmony valve do not require additional measures and should continue usual follow-up care.
  • Manufacturer Instructions: Medtronic instructed customers to quarantine and return affected devices and notify relevant parties.
Key Findings:
  • Manufacturing issue can increase likelihood of distal tip detachment.
  • Recall limited to the delivery catheter, not the implanted valve.
  • No serious injuries or deaths reported as of May 14, 2026.
Interpretation:

The recall highlights a significant manufacturing concern that could impact procedural safety.

Limitations:
  • Recall does not affect the implanted valve, limiting the scope of patient impact.
Conclusion:

Patients should remain informed but continue with standard follow-up care.

Sources:

Original Source(s)

FDA Classifies Medtronic Harmony Recall as Class I

  • by Kathryn Wighton

  • July 15, 2026

Related Content

Can Sugammadex Lower Postsurgical Pulmonary Complications?

A large international randomized trial found fewer postoperative pulmonary complications with sugammadex vs. neostigmine following major abdominal or thoracic surgery, although the difference was driven primarily by reduced atelectasis.

Consensus Panel Calls for Enhanced Radiation Shielding

A consensus statement called for immediate adoption of enhanced radiation protection devices, although evidence of long-term health benefits and effectiveness across procedural settings remains limited.

Case report: Additional Imaging Supports TAPVR Care

A case report shows that advanced cardiac CT and MRI imaging can improve surgical planning and reintervention for patients with infradiaphragmatic total anomalous pulmonary venous return (TAPVR). See what Sebastián Quiñones-Carrasquillo, MD, and co-authors Todd Nowlen, MD and Daniel Velez, MD, recommend for using these advanced diagnostic imaging modalities.

  • by

  • August 12, 2026

  • 6 min